FDA Advisory Committee supports the use of Novartis inhalation powder, Tobramycin

The FDA Advisory Committee voted 13 to 1 that research showed adequate evidence to support the use of tobramycin inhalation powder by cystic fibrosis patients whose lungs contain the bacteria Pseudomonas aeruginosa, the leading cause of lung function loss in patients with CF. Tobramycin inhalation powder (TIP) is intended for CF patients over the age of six whose lung function is within a specific range. Currently, TIP is approved in 38 countries.

To learn more about TIP, please see the Novartis Press Release.